Stockwatch: Coronavirus And Commercialization
Crisis Profits Unlikely For Pharma And Biotech Firms
Executive Summary
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
You may also be interested in...
Sandoz, Teva And Mylan Step Up On Hydroxychloroquine
To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.
Coronavirus Update: Fujifilm Drug Shows Promise, Arrowhead Halts Trial Screening, Novartis Unveils COVID-19 Measures
Flu drug produces encouraging results in Chinese trials, while Novartis CEO Vas Narasimhan shows his public health background with package of measures.
Some Caution Over 'People’s Hope' Remdesivir As China Trials Progress
Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.